Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is currently under investigation by Johnson Fistel, PLLP, a renowned shareholder-rights law firm, regarding potential claims related to investor losses. The firm is focusing on whether the company’s executive officers may have violated federal securities laws, which could impact shareholders who have incurred losses.

The investigation was prompted by troubling events in August and November 2025. On August 12, Zevra disclosed a significant $11.7 million inventory write-down during its second-quarter financial results, which led to a steep 25% drop in its stock price. Further compounding these issues, on November 20, the resignation of the Chief Financial Officer was announced, resulting in another decline of approximately 18% in share price within the subsequent trading days. These developments have raised questions regarding the company's compliance with securities regulations and its overall transparency with investors.

Shareholders who have purchased Zevra securities and have experienced financial losses are encouraged to reach out to Johnson Fistel for assistance in potentially recovering their losses. The firm emphasizes that this inquiry involves no cost or obligation for potential claimants. Interested investors can join the investigation by contacting Jim Baker at jimb@johnsonfistel.com or by calling (619) 814-4471.

Johnson Fistel has a strong track record, having recovered around $90.7 million for clients in previous cases, and has been recognized multiple times as a leading plaintiff firm in securities law. For more information about their services, investors can visit their website at www.johnsonfistel.com. This investigation represents a vital opportunity for affected shareholders to seek justice and potential recovery for their losses in Zevra Therapeutics.

Zevra Therapeutics (NASDAQ: ZVRA) has recently faced significant challenges that have prompted an investigation by Johnson Fistel, PLLP, concerning potential claims for shareholders who have suffered losses. If you are an investor in Zevra, it is crucial to assess your position and consider your options moving forward.

The significant stock price declines of approximately 25% following the announcement of an $11.7 million inventory write-down and an additional 18% drop after the resignation of the Chief Financial Officer raise serious concerns about the firm's governance and financial disclosures. These events could imply that Zevra's leadership may not have complied with federal securities laws, which obligate them to provide accurate and transparent information to shareholders. The implications of this situation warrant a careful evaluation of both your investment strategy and the possibility of recovering losses.

If you've purchased Zevra securities and experienced a financial setback, participating in the investigation initiated by Johnson Fistel could be a prudent step. There is no financial obligation, and joining this investigation could provide insight into potential recovery avenues available to you under applicable securities laws.

It is advisable to reach out for more information either by contacting Jim Baker at Johnson Fistel directly or through their website. Given the law firm's strong track record of recovering substantial losses—having secured over $90 million for aggrieved clients—you may have legitimate grounds for pursuing compensation for your losses.

In conclusion, if you're a Zevra shareholder, take proactive measures by engaging with Johnson Fistel to understand your rights and any possible recovery actions. Market conditions and firm disclosures can shift rapidly, so timely action is crucial. Your investment decisions should be well-informed and consider legal avenues for potential recovery.